180 related articles for article (PubMed ID: 37985574)
1. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
[TBL] [Abstract][Full Text] [Related]
2. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures.
Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC
J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
4. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users.
Chou AC; Ng AC; Png MA; Chua DT; Ng DC; Howe TS; Koh JS
Bone; 2015 Oct; 79():170-5. PubMed ID: 26067179
[TBL] [Abstract][Full Text] [Related]
7. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
Lee SH; Lee YH; Suh JS
AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
[TBL] [Abstract][Full Text] [Related]
8. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
van de Laarschot DM; McKenna MJ; Abrahamsen B; Langdahl B; Cohen-Solal M; GuaƱabens N; Eastell R; Ralston SH; Zillikens MC
J Clin Endocrinol Metab; 2020 May; 105(5):1682-99. PubMed ID: 31867670
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population - Secondary analysis.
Gani LU; Anthony NF; Dacay LM; Tan PT; Chong LR; King TFJ
Bone; 2022 Sep; 162():116455. PubMed ID: 35688361
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
Gedmintas L; Solomon DH; Kim SC
J Bone Miner Res; 2013 Aug; 28(8):1729-37. PubMed ID: 23408697
[TBL] [Abstract][Full Text] [Related]
11. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
12. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
[TBL] [Abstract][Full Text] [Related]
13. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC
Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850
[TBL] [Abstract][Full Text] [Related]
15. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Adler RA
Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
[TBL] [Abstract][Full Text] [Related]
16. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
[TBL] [Abstract][Full Text] [Related]
17. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture.
Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW
J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433
[TBL] [Abstract][Full Text] [Related]
18. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis treatment rate following hip fracture in a community hospital.
Khan AA; AbuAlrob H; Tariq F; Tauqir M; Zalzal P; M'Hiri I; Khan M; Ginty M; Weening B
Arch Osteoporos; 2021 Jan; 16(1):8. PubMed ID: 33409668
[TBL] [Abstract][Full Text] [Related]
20. Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates.
Watts NB; Aggers D; McCarthy EF; Savage T; Martinez S; Patterson R; Carrithers E; Miller PD
J Bone Miner Res; 2017 May; 32(5):1027-1033. PubMed ID: 28071822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]